The Genesis Solar Wind Concentrator

The primary goal of the Genesis Mission is to collect solar wind ions and, from their analysis, establish key isotopic ratios that will help constrain models of solar nebula formation and evolution. The ratios of primary interest include ^(17)O/^(16)O and ^(18)O/^(16)O to ±0.1%, ^(15)N/^(14)N to ±1%, and the Li, Be, and B elemental and isotopic abundances. The required accuracies in N and O ratios cannot be achieved without concentrating the solar wind and implanting it into low-background target materials that are returned to Earth for analysis. The Genesis Concentrator is designed to concentrate the heavy ion flux from the solar wind by an average factor of at least 20 and implant it into a target of ultra-pure, well-characterized materials. High-transparency grids held at high voltages are used near the aperture to reject >90% of the protons, avoiding damage to the target. Another set of grids and applied voltages are used to accelerate and focus the remaining ions to implant into the target. The design uses an energy-independent parabolic ion mirror to focus ions onto a 6.2 cm diameter target of materials selected to contain levels of O and other elements of interest established and documented to be below 10% of the levels expected from the concentrated solar wind. To optimize the concentration of the ions, voltages are constantly adjusted based on real-time solar wind speed and temperature measurements from the Genesis ion monitor. Construction of the Concentrator required new developments in ion optics; materials; and instrument testing and handling

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN